Clinical Trial Detail

NCT ID NCT02639091
Title Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

peritoneal mesothelioma

malignant pleural mesothelioma

lung non-small cell carcinoma

Therapies

Anetumab ravtansine + Cisplatin + Pemetrexed Disodium

Age Groups: adult senior

No variant requirements are available.